Allarity Therapeutics Inc ALLR

$ALLR Brilliant piece that captures ALLR's situation perfectly. So if you want to update your understanding of ALLR or get to know ALLR better, this is essential reading. https://everyticker.com/quote/ALLR/analysis/stenoparib-s-precision-gamble-allarity-s-race-against-capital-and-competition-in-parp-inhibition-nasdaq-allr

$ALLR Woo, Senior Analyst for Ascendiant Capital, sole $11 broker rating Allarity has an ATM agreement under which Ascendiant acts as the sales agent for ALLR shares and receives a 3% commission on shares sold through the facility. Allarity's SEC filing explicitly discloses that relationship... JFC

$ALLR 💎💎

🧬 $ALLR is strengthening the case for DRP-guided stenoparib development Allarity is tightening its strategy around the Drug Response Predictor (DRP), with recent patent awards and CLIA certification adding support for stenoparib's clinical and commercial path. Key takeaways: • The stenoparib-DRP uses a 414-gene expression signature to identify patients more likely to respond • AACR 2026 data showed higher pretreatment DRP scores were associated with longer overall survival in a prior Phase 2 ovarian cancer cohort • Recent patent awards strengthen protection for stenoparib used with the DRP® companion diagnostic • The company's CLIA-certified in-house laboratory gives Allarity control over DRP testing for U.S. clinical trials • Allarity plans to use DRP-guided patient selection as an integral part of stenoparib's development toward FDA approval Price target breakdown here 👇 https://www.zacks.com/stock/research/ALLR/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-39771&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_39771

$ALLR outlined recent advances in its DRP technology, patent portfolio and lab capabilities to support stenoparib development.

@EquivalentExchange is on an absolute tear recently🔥the plays just keep getting better! If you’re not following yet you’re missing out. $LICN $TDTH $ALLR soon

$ALLR webull $BULL always late We got news at the bottom where the mgmt bought before

$ALLR Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development - Recently awarded patents have solidified Allarity’s strategy to leverage DRP to ensure the commercial exclusivity of stenoparib